Cadrenal Therapeutics, Inc.
CVKD
$15.50
-$0.775-4.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 63.62% | 38.15% | |||
| Depreciation & Amortization | 0.00% | -20.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 73.92% | -0.27% | |||
| Operating Income | -73.92% | 0.27% | |||
| Income Before Tax | -73.91% | -0.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -73.91% | -0.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -73.91% | -0.62% | |||
| EBIT | -73.92% | 0.27% | |||
| EBITDA | -73.93% | 0.26% | |||
| EPS Basic | -17.08% | 2.73% | |||
| Normalized Basic EPS | -17.09% | 2.73% | |||
| EPS Diluted | -17.08% | 2.73% | |||
| Normalized Diluted EPS | -17.09% | 2.73% | |||
| Average Basic Shares Outstanding | 48.52% | 3.45% | |||
| Average Diluted Shares Outstanding | 48.52% | 3.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||